Scarica l'app Stockscreener
1.34
8.22%
-0.12
Dopo l'orario di chiusura:
1.38
0.04
+2.99%
Precedente Chiudi:
$1.46
Aprire:
$1.44
Volume 24 ore:
2.45M
Relative Volume:
0.67
Capitalizzazione di mercato:
$59.52M
Reddito:
-
Utile/perdita netta:
$-51.50M
Rapporto P/E:
-0.335
EPS:
-4
Flusso di cassa netto:
$-47.10M
1 W Prestazione:
+8.94%
1M Prestazione:
+24.07%
6M Prestazione:
-2.19%
1 anno Prestazione:
-74.18%
Intervallo 1D:
$1.31
$1.44
Intervallo di 1 settimana:
$1.18
$1.54
Portata 52W:
$0.79
$6.98
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Nome
Outlook Therapeutics Inc
Settore
Industria
Telefono
(609) 619-3990
Indirizzo
111 S. WOOD AVENUE, ISELIN, NJ
Confronta OTLK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.34 | 63.96M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-02 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-02-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-27 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-08-30 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-07-13 | Iniziato | CapitalOne | Overweight |
| 2023-04-03 | Iniziato | Guggenheim | Buy |
| 2023-02-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Iniziato | BTIG Research | Buy |
| 2022-09-13 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2019-05-16 | Iniziato | Oppenheimer | Outperform |
| 2019-04-22 | Iniziato | Ascendiant Capital Markets | Buy |
Mostra tutto
Outlook Therapeutics Inc Borsa (OTLK) Ultime notizie
Outlook Therapeutics Inc. stock prediction for this weekJuly 2025 Final Week & Daily Profit Focused Stock Screening - newser.com
How Outlook Therapeutics Inc. (41ON) stock moves in volatile trading sessionsJuly 2025 Trends & Fast Gaining Stock Strategy Reports - newser.com
Outlook Therapeutics Inc 41O Stock Analysis and ForecastMoving Average Strategies & Stocks With 200% Upside Potential - earlytimes.in
What does recent volatility data suggest for Outlook Therapeutics Inc.July 2025 Movers & Accurate Intraday Trading Signals - newser.com
What is the fair value of Outlook Therapeutics Inc. stock nowTrade Volume Report & Real-Time Sentiment Analysis - newser.com
Full technical analysis of Outlook Therapeutics Inc. stockMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Custom strategy builders for tracking Outlook Therapeutics Inc.Fed Meeting & Fast Gain Stock Tips - newser.com
Will Outlook Therapeutics Inc. (41ON) stock outperform value peersJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - newser.com
Can Outlook Therapeutics Inc. stock continue upward trendJuly 2025 Momentum & Daily Profit Focused Screening - newser.com
News impact scoring models applied to Outlook Therapeutics Inc.2025 Valuation Update & Long Hold Capital Preservation Tips - newser.com
Can Outlook Therapeutics Inc. stock beat analyst upgradesQuarterly Performance Summary & Technical Pattern Based Signals - newser.com
What analysts say about Outlook Therapeutics Inc 41ON stockRisk-Reward Ratio Analysis & Superior Wealth Growth - earlytimes.in
What earnings revisions data tells us about Outlook Therapeutics Inc. - newser.com
Real time pattern detection on Outlook Therapeutics Inc. stockBull Run & Verified Stock Trade Ideas - newser.com
Applying sector rotation models to Outlook Therapeutics Inc.Bear Alert & Verified Trade Idea Suggestions - newser.com
Is Outlook Therapeutics Inc. (41ON) stock good for long term investingEarnings Summary Report & AI Driven Stock Movement Reports - newser.com
Is Outlook Therapeutics Inc a good long term investmentStock Buyback Announcements & Exceptional Trading Strategies - earlytimes.in
How sentiment analysis helps forecast Outlook Therapeutics Inc.M&A Rumor & Real-Time Sentiment Analysis - newser.com
Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Weiss Ratings Reaffirms "Sell (E+)" Rating for Oncobiologics (NASDAQ:OTLK) - MarketBeat
How Outlook Therapeutics Inc. (41ON) stock expands through international marketsWeekly Investment Recap & Capital Efficient Trading Techniques - newser.com
Can Outlook Therapeutics Inc. rally from current levels2025 Sector Review & Stock Portfolio Risk Control - newser.com
How Outlook Therapeutics Inc. stock performs in interest rate cyclesQuarterly Profit Review & Weekly High Potential Stock Alerts - newser.com
Market reaction to Outlook Therapeutics Inc.’s recent newsShare Buyback & Safe Entry Point Alerts - newser.com
How to recover losses in Outlook Therapeutics Inc. stockJuly 2025 Selloffs & Consistent Income Trade Ideas - newser.com
Sentiment analysis tools applied to Outlook Therapeutics Inc.July 2025 Retail & Risk Adjusted Buy/Sell Alerts - newser.com
Why Outlook Therapeutics Inc. (41ON) stock is favored by hedge fundsPortfolio Return Report & Low Risk High Win Rate Picks - newser.com
Is Outlook Therapeutics Inc. (41ON) stock attractive for growth fundsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Outlook Therapeutics Inc Azioni (OTLK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):